A human colon cancer cell capable of initiating tumour growth in immunodeficient mice (original) (raw)

Nature volume 445, pages 106–110 (2007)Cite this article

Abstract

Colon cancer is one of the best-understood neoplasms from a genetic perspective1,2,3, yet it remains the second most common cause of cancer-related death, indicating that some of its cancer cells are not eradicated by current therapies4,5. What has yet to be established is whether every colon cancer cell possesses the potential to initiate and sustain tumour growth, or whether the tumour is hierarchically organized so that only a subset of cells—cancer stem cells—possess such potential6,7. Here we use renal capsule transplantation in immunodeficient NOD/SCID mice to identify a human colon cancer-initiating cell (CC-IC). Purification experiments established that all CC-ICs were CD133+; the CD133- cells that comprised the majority of the tumour were unable to initiate tumour growth. We calculated by limiting dilution analysis that there was one CC-IC in 5.7 × 104 unfractionated tumour cells, whereas there was one CC-IC in 262 CD133+ cells, representing >200-fold enrichment. CC-ICs within the CD133+ population were able to maintain themselves as well as differentiate and re-establish tumour heterogeneity upon serial transplantation. The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem cells.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal cancer tumorigenesis. Cell 61, 759–767 (1990)
    Article CAS Google Scholar
  2. Fearon, E. R. & Jones, P. A. Progressing toward a molecular description of colorectal cancer development. FASEB J. 6, 2783–2790 (1992)
    Article CAS Google Scholar
  3. Radtke, F. & Clevers, H. Self-renewal and cancer of the gut: two sides of a coin. Science 307, 1904–1909 (2005)
    Article CAS ADS Google Scholar
  4. Nelson, H. et al. Guidelines 2000 for colon and rectal cancer surgery. J. Natl Cancer Inst. 93, 583–596 (2001)
    Article CAS Google Scholar
  5. O'Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl Cancer Inst. 96, 1420–1425 (2004)
    Article Google Scholar
  6. Dick, J. E. Breast cancer stem cells revealed. Proc. Natl Acad. Sci. USA 100, 3547–3549 (2003)
    Article CAS ADS Google Scholar
  7. Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005)
    Article CAS Google Scholar
  8. Pocard, M., Tsukui, H., Salmon, R. J., Dutrillaux, B. & Poupon, M. F. Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 10, 463–469 (1996)
    CAS PubMed Google Scholar
  9. Ravi, R. et al. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 64, 9105–9114 (2004)
    Article CAS Google Scholar
  10. Golas, J. M. et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 65, 5358–5364 (2005)
    Article CAS Google Scholar
  11. Sack, M. J. & Roberts, S. A. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn. Cytopathol. 16, 132–136 (1997)
    Article CAS Google Scholar
  12. Ishida, H. et al. Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer. Cancer Lett. 207, 109–115 (2004)
    Article CAS Google Scholar
  13. Liang, J. T. et al. Microvessel density, cyclo-oxygenase 2 expression, K-ras mutation and p53 overexpression in colonic cancer. Br. J. Surg. 91, 355–361 (2004)
    Article CAS Google Scholar
  14. Porter, E. H. & Berry, R. J. The efficient design of transplantable tumour assays. Br. J. Cancer 17, 583–595 (1964)
    Article Google Scholar
  15. Wang, J. C., Doedens, M. & Dick, J. E. Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. Blood 89, 3919–3924 (1997)
    CAS PubMed Google Scholar
  16. Al Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003)
    Article CAS ADS Google Scholar
  17. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004)
    Article CAS ADS Google Scholar
  18. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001)
    Article CAS ADS Google Scholar
  19. Marzesco, A. M. et al. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J. Cell Sci. 118, 2849–2858 (2005)
    Article CAS Google Scholar
  20. Corbeil, D. et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J. Biol. Chem. 275, 5512–5520 (2000)
    Article CAS Google Scholar
  21. Madlambayan, G. J. et al. Dynamic changes in cellular and microenvironmental composition can be controlled to elicit in vitro human hematopoietic stem cell expansion. Exp. Hematol. 33, 1229–1239 (2005)
    Article CAS Google Scholar
  22. Lapidot, T. et al. A cell initiating human acute myeloid leukemia after transplantation into SCID mice. Nature 367, 645–648 (1994)
    Article CAS ADS Google Scholar
  23. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature Immunol. 5, 738–743 (2004)
    Article CAS Google Scholar
  24. Al Hajj, M. & Clarke, M. F. Self-renewal and solid tumor stem cells. Oncogene 23, 7274–7282 (2004)
    Article CAS Google Scholar
  25. Polyak, K. & Hahn, W. C. Roots and stems: stem cells in cancer. Nature Med. 12, 296–300 (2006)
    Article CAS Google Scholar
  26. Al Hajj, M., Becker, M. W., Wicha, M., Weissman, I. & Clarke, M. F. Therapeutic implications of cancer stem cells. Curr. Opin. Genet. Dev. 14, 43–47 (2004)
    Article CAS Google Scholar

Download references

Acknowledgements

We gratefully acknowledge assistance from F. Meng, H. Begley and C. Ash for tissue acquisition, D. Hedley for advice on establishment of the xenograft model, J Wang for assistance with manuscript preparation, and the Dick laboratory members, P. Dirks and D.Hill for comments on the manuscript. We also acknowledge K. So and the University Health Network Pathology Research Program for tissue sectioning and immunohistochemistry. This work was supported by: a clinician-scientist award (C.A.O’B.), and grants (J.E.D.) from the Canadian Institute of Health Research, as well as grants to J.E.D. from Genome Canada through the Ontario Genomics Institute, the Ontario Cancer Research Network with funds from the Province of Ontario, the Leukemia and Lymphoma Society, the National Cancer Institute of Canada with funds from the Canadian Cancer Society and the Terry Fox Foundation, and a Canada Research Chair (J.E.D.). Author Contributions C.A.O'B. planned the project, carried out experimental work, analysed data and prepared the manuscript. A.P. provided pathology analysis. S.G. provided clinical information and human tissues. J.E.D. planned the project, analysed data, and prepared the manuscript.

Author information

Authors and Affiliations

  1. Division of Cell and Molecular Biology, University Health Network, Ontario, M5G 1L7, Toronto, Canada
    Catherine A. O’Brien & John E. Dick
  2. Department of Pathology and Laboratory Medicine,
    Aaron Pollett
  3. Center for Cancer Genetics-Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Ontario, M5G 1X5, Toronto, Canada
    Steven Gallinger
  4. Department of Molecular and Medical Genetics, University of Toronto, Ontario, M5S 1A8, Toronto, Canada
    John E. Dick

Authors

  1. Catherine A. O’Brien
    You can also search for this author inPubMed Google Scholar
  2. Aaron Pollett
    You can also search for this author inPubMed Google Scholar
  3. Steven Gallinger
    You can also search for this author inPubMed Google Scholar
  4. John E. Dick
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toJohn E. Dick.

Ethics declarations

Competing interests

Reprints and permissions information is available at www.nature.com/reprints. The authors declare no competing financial interests.

Supplementary information

Supplementary Figures

This file contains Supplementary Figures 1–4. Supplementary Figure 1: Unfractionated and CD133+ colon cancer cells initiate tumors when transplanted under the renal capsule of NOD/SCID mice. Supplementary Figure 2: Flow cytometric analysis of CD133 and ESA expression. Supplementary Figure 3: Histological examination following injection of CD133- colon cancer cells. Supplementary Figure 4: Analysis of purity following magnetic bead separation (PDF 1021 kb)

Supplementary Methods

This file contains additional details on the methods used in this study. (DOC 28 kb)

Rights and permissions

About this article

Cite this article

O’Brien, C., Pollett, A., Gallinger, S. et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.Nature 445, 106–110 (2007). https://doi.org/10.1038/nature05372

Download citation

This article is cited by

Editorial Summary

Cancer stem cells

Two papers in this issue report the identification of a specific type of colon cancer cell that initiates tumour growth in mice. This lends support to the theory that only a few cells within a tumour, the cancer stem cells, are responsible for tumour formation and maintenance. The finding highlights the importance of finding therapeutics to target cancer stem cells.